The following trials provide information to treat various types of cardiovascular diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A phase IV, 6-week, randomised, double-blind, multicentre, parallel group, comparative study to evaluate the efficacy of rosuvastatin 5mg and atorvastatin 10mg in UK Asian subjects with primary hypercholesterolaemia.
- collapse A 6-week, randomised, open-label, parallel group, multi-centre study to compare the efficacy of rosuvastain 10mg with atorvastatin 10mg in the treatment of non-diabetic metabolic syndrome subjects with raised LDL-C
- collapse A randomised, double-blind, parallel-group, multicentre study comparing the efficacy of rosuvastatin 10 mg (with a possible titration to 40 mg) with atorvastatin 20 mg (with a possible titration to 80 mg) when given for a period of 16 weeks to subjects with coronary heart disease and a previously performed percutaneous coronary intervention
- collapse An open-label, randomised, multi-centre, phase IIIb/IV, parallel group study to compare the efficacy and safety of rosuvastatin and atorvastatin in subjects with type IIa and IIb hypercholesterolaemia (DISCOVERY)
- collapse ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
- collapse Effect of an Internet based compliance enhancement tool in subjects with hypercholesterolemia
- collapse Effects of a twelve months ROSUVASTATIN treatment plus additional care (drug intake adherence and lifestyle enhancing initiatives ) compared to ROSUVASTATIN treatment alone on long-term disease-related costs in patients with an indication for statin treatment according to the Joint European Guidelines
- collapse Randomized, Double-Blind, multicenter, trial to assess the effect of high & Low doses of ZD4522 on progression of Carotid Artery Atheroma in moderately Hypercholesterolemic subjects with Asymptomatic Carotid Stenosis after 24 months of dosing.
- collapse A phase I, open-label, pharmacokinetic study measuring plasma exposure of a 20 mg single dose administration of rosuvastatin calcium to healthy Asian subjects living in the United States related to the pharmacokinetic data obtained from a Caucasian control group
- collapse A randomized, open-label, 2 way crossover study to assess the reciprocal effects of co-administration of rosuvastatin 40 mg and ezetimibe 10 mg on the steady-state pharmacokinetics of each drug
